Risk of drug-induced liver injury in chronic hepatitis C and tuberculosis co– infection: a systematic review and meta– analysis

This meta-analysis suggests that the prevalence of DILI in patients with HCV is higher than in those without HCV. Routine HCV screening before the initiation of TB therapy is critically important for the early identification of HCV-TB co-infection, enabling clinicians to modify TB and HCV treatment and management to mitigate the risks of DILI. Close follow-up and regular liver test monitoring are indispensable for the treatment of TB in chronic hepatitis C carriers.